JP2004504029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504029A5 JP2004504029A5 JP2002512356A JP2002512356A JP2004504029A5 JP 2004504029 A5 JP2004504029 A5 JP 2004504029A5 JP 2002512356 A JP2002512356 A JP 2002512356A JP 2002512356 A JP2002512356 A JP 2002512356A JP 2004504029 A5 JP2004504029 A5 JP 2004504029A5
- Authority
- JP
- Japan
- Prior art keywords
- krab
- domain
- seq
- polypeptide
- sid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 67
- 102000004196 processed proteins & peptides Human genes 0.000 description 55
- 229920001184 polypeptide Polymers 0.000 description 52
- 239000002773 nucleotide Substances 0.000 description 40
- 238000009739 binding Methods 0.000 description 35
- 230000004568 DNA-binding Effects 0.000 description 34
- 230000027455 binding Effects 0.000 description 34
- 108020001756 ligand binding domains Proteins 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 34
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 30
- 239000011701 zinc Substances 0.000 description 30
- 229910052725 zinc Inorganic materials 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 125000000539 amino acid group Chemical group 0.000 description 26
- 102000037865 fusion proteins Human genes 0.000 description 25
- 108020001507 fusion proteins Proteins 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 21
- 239000005089 Luciferase Substances 0.000 description 20
- 108060001084 Luciferase Proteins 0.000 description 18
- 230000004927 fusion Effects 0.000 description 18
- 229940088597 hormone Drugs 0.000 description 17
- 239000005556 hormone Substances 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000003446 ligand Substances 0.000 description 14
- 230000001419 dependent effect Effects 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- 108010057988 ecdysone receptor Proteins 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 11
- 102000034527 Retinoid X Receptors Human genes 0.000 description 10
- 108010038912 Retinoid X Receptors Proteins 0.000 description 10
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 101710185494 Zinc finger protein Proteins 0.000 description 9
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108091027981 Response element Proteins 0.000 description 6
- 101000882586 Mus musculus Estrogen receptor Proteins 0.000 description 5
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 5
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- -1 4-dimethylaminophenyl Chemical group 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 101000574060 Homo sapiens Progesterone receptor Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108700026226 TATA Box Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000003998 progesterone receptors Human genes 0.000 description 4
- 108090000468 progesterone receptors Proteins 0.000 description 4
- 230000014493 regulation of gene expression Effects 0.000 description 4
- 230000037425 regulation of transcription Effects 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PJYYBCXMCWDUAZ-JJJZTNILSA-N 2,3,14,20,22-pentahydroxy-(2β,3β,5β,22R)-Cholest-7-en-6-one Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 PJYYBCXMCWDUAZ-JJJZTNILSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- PJYYBCXMCWDUAZ-YKDQUOQBSA-N Ponasterone A Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 PJYYBCXMCWDUAZ-YKDQUOQBSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 102000005969 steroid hormone receptors Human genes 0.000 description 3
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100024630 Asc-type amino acid transporter 1 Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 101100442582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) spe-1 gene Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101150081875 Slc7a10 gene Proteins 0.000 description 2
- 101150052859 Slc9a1 gene Proteins 0.000 description 2
- 108010085012 Steroid Receptors Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- WFPOBMHQGIPWFB-GCLUAJDJSA-N (7s,8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-7,13-dimethylspiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one Chemical compound C([C@@H]1[C@]2(C)C[C@@H](C3=C4CCC(=O)C=C4C[C@@H]([C@@H]13)C)C=1C=CC(=CC=1)N(C)C)C[C@@]21CCCO1 WFPOBMHQGIPWFB-GCLUAJDJSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101100462537 Caenorhabditis elegans pac-1 gene Proteins 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101001006782 Homo sapiens Kinesin-associated protein 3 Proteins 0.000 description 1
- 101000753286 Homo sapiens Transcription intermediary factor 1-beta Proteins 0.000 description 1
- 101000818735 Homo sapiens Zinc finger protein 10 Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100117764 Mus musculus Dusp2 gene Proteins 0.000 description 1
- 101710153661 Nuclear receptor corepressor 1 Proteins 0.000 description 1
- 102100022935 Nuclear receptor corepressor 1 Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102100023715 Poly(A)-specific ribonuclease PARN Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006289 Transcription Factor TFIIA Human genes 0.000 description 1
- 108010083262 Transcription Factor TFIIA Proteins 0.000 description 1
- 108010068068 Transcription Factor TFIIIA Proteins 0.000 description 1
- 102100028509 Transcription factor IIIA Human genes 0.000 description 1
- 102100022012 Transcription intermediary factor 1-beta Human genes 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 102100021112 Zinc finger protein 10 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61906300A | 2000-07-18 | 2000-07-18 | |
| PCT/EP2001/008190 WO2002006463A2 (en) | 2000-07-18 | 2001-07-16 | Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004504029A JP2004504029A (ja) | 2004-02-12 |
| JP2004504029A5 true JP2004504029A5 (cg-RX-API-DMAC7.html) | 2006-01-05 |
Family
ID=24480304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002512356A Withdrawn JP2004504029A (ja) | 2000-07-18 | 2001-07-16 | 単鎖、一量体、リガンド依存性ポリペプチドスイッチを用いる遺伝子発現の調節 |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP1303606B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004504029A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE382691T1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU7254401A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2415726A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60132208T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2299494T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL153833A0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ523649A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002006463A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
| US7011972B2 (en) | 2000-07-18 | 2006-03-14 | The Scripps Research Institute | Fusion polypeptide comprising two ligand binding domains |
| US7070993B2 (en) | 2001-03-13 | 2006-07-04 | Novartis Ag | Lentiviral packaging constructs |
| DE60228082D1 (de) | 2001-05-31 | 2008-09-18 | Novartis Ag | Nten und neue liganden und pharmazeutische zusammensetzungen |
| US7927840B2 (en) | 2006-09-11 | 2011-04-19 | Gen Probe Incorporated | Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region |
| CA2501946C (en) | 2002-10-16 | 2014-12-23 | Gen-Probe Incorporated | Compositions and methods for detecting west nile virus |
| WO2022049217A1 (en) * | 2020-09-04 | 2022-03-10 | Miltenyi Biotec B.V. & Co. KG | System for inducible expression of an adapter in immune cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4981784A (en) * | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| EP0935657B1 (en) * | 1996-10-29 | 2007-08-29 | Baylor College Of Medicine | Modified steroid hormone receptors |
| JP2003524368A (ja) * | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| CA2323064C (en) * | 1998-03-17 | 2011-05-31 | Gendaq Limited | Nucleic acid binding proteins |
| US6140081A (en) * | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US7057015B1 (en) * | 1999-10-20 | 2006-06-06 | The Salk Institute For Biological Studies | Hormone receptor functional dimers and methods of their use |
| US7329728B1 (en) * | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
-
2001
- 2001-07-16 JP JP2002512356A patent/JP2004504029A/ja not_active Withdrawn
- 2001-07-16 EP EP01951681A patent/EP1303606B1/en not_active Expired - Lifetime
- 2001-07-16 AU AU7254401A patent/AU7254401A/xx active Pending
- 2001-07-16 AT AT01951681T patent/ATE382691T1/de not_active IP Right Cessation
- 2001-07-16 ES ES01951681T patent/ES2299494T3/es not_active Expired - Lifetime
- 2001-07-16 EP EP07019198A patent/EP1908835A3/en not_active Withdrawn
- 2001-07-16 AU AU2001272544A patent/AU2001272544B2/en not_active Ceased
- 2001-07-16 IL IL15383301A patent/IL153833A0/xx unknown
- 2001-07-16 WO PCT/EP2001/008190 patent/WO2002006463A2/en not_active Ceased
- 2001-07-16 CA CA002415726A patent/CA2415726A1/en not_active Abandoned
- 2001-07-16 NZ NZ523649A patent/NZ523649A/en unknown
- 2001-07-16 DE DE60132208T patent/DE60132208T2/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7011972B2 (en) | Fusion polypeptide comprising two ligand binding domains | |
| US7329728B1 (en) | Ligand activated transcriptional regulator proteins | |
| Wang et al. | Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator | |
| Beerli et al. | Chemically regulated zinc finger transcription factors | |
| KR100659922B1 (ko) | Ｇｎｎ에 대한 아연 핑거 결합 도메인 | |
| CA2200423C (en) | Novel estrogen receptor | |
| Moore et al. | Recent developments in the engineering of zinc finger proteins | |
| JP2004504029A5 (cg-RX-API-DMAC7.html) | ||
| Cato et al. | Regulation of gene expression by steroid hormones | |
| EP1303606B1 (en) | Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches | |
| AU2001272544A1 (en) | Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches | |
| Gavva et al. | NAPP2, a peroxisomal membrane protein, is also a transcriptional corepressor | |
| AU2005234684B2 (en) | Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches | |
| HK1115159A (en) | Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches | |
| Archer et al. | Modulation of transcription factor access and activity at the MMTV promoter in vivo | |
| Hadzic | Elucidating mechanisms by which T3Rs activate transcription of target genes | |
| ARCHER et al. | Modulation of Transcription Factor Access and Activity at the MMTV | |
| HK1001978B (en) | Estrogen receptor |